Literature DB >> 18505979

Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease.

P Laforêt1, P Petiot, M Nicolino, D Orlikowski, C Caillaud, N Pellegrini, R Froissart, T Petitjean, I Maire, H Chabriat, L Hadrane, D Annane, B Eymard.   

Abstract

BACKGROUND: Strokes related to intracranial aneurysm or arteriopathy have been reported in a few patients with late-onset Pompe disease. These reports suggested that cerebral vessel involvement could be an underrecognized complication of this disease.
METHODS: We report cerebral artery involvement in three French patients with late-onset Pompe disease.
RESULTS: The first patient died at age 35 years from complications of a giant fusiform aneurysm of the basilar artery, and her 34-year-old sister showed evidence of dolichoectatic basilar artery on magnetic resonance angiography. A dilative arteriopathy complicated with carotid artery dissection was diagnosed in the third patient, aged 50 years. Two patients are currently being treated with enzyme replacement therapy (alglucosidase alfa), and regular angiographic follow-up showed the absence of progression of vascular abnormalities in one of them.
CONCLUSION: These observations, combined with previously reported cases, confirm that Pompe disease should be recognized as a predisposing condition to dilative arteriopathy and cerebral aneurysm formation, although the real incidence of these vascular complications remains unknown.

Entities:  

Mesh:

Year:  2008        PMID: 18505979     DOI: 10.1212/01.wnl.0000313367.09469.13

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism.

Authors:  George Chinedu Ezeji; Taiga Inoue; Gul Bahtiyar; Alan Sacerdote
Journal:  BMJ Case Rep       Date:  2015-02-09

Review 2.  Dolichoectasia-an evolving arterial disease.

Authors:  Jose Gutierrez; Ralph L Sacco; Clinton B Wright
Journal:  Nat Rev Neurol       Date:  2011-01       Impact factor: 42.937

3.  Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts.

Authors:  Véronique Quenardelle; Marc Bataillard; Dorothée Bazin; Béatrice Lannes; Valérie Wolff; Andoni Echaniz-Laguna
Journal:  J Neurol       Date:  2014-12-02       Impact factor: 4.849

4.  Diffuse cerebral microhemorrhages in a patient with adult-onset Pompe's disease: a case report.

Authors:  Divyajot Sandhu; Adam Rizvi; Jae Kim; Rwoof Reshi
Journal:  J Vasc Interv Neurol       Date:  2014-12

5.  Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.

Authors:  Loren D M Pena; Alan D Proia; Priya S Kishnani
Journal:  JIMD Rep       Date:  2015-03-13

6.  Late-onset Pompe disease: a genetic-radiological correlation on cerebral vascular anomalies.

Authors:  A Pichiecchio; S Sacco; P De Filippi; E Caverzasi; S Ravaglia; S Bastianello; C Danesino
Journal:  J Neurol       Date:  2017-08-30       Impact factor: 4.849

7.  Dolichoectasia diagnostic methods in a multi-ethnic, stroke-free cohort: results from the northern Manhattan study.

Authors:  Jose Gutierrez; Ahmet Bagci; Hannah Gardener; Tatjana Rundek; Mitchell S V Ekind; Noam Alperin; Ralph L Sacco; Clinton B Wright
Journal:  J Neuroimaging       Date:  2013-01-14       Impact factor: 2.486

8.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

9.  Altered energy state reversibly controls smooth muscle contractile function in human saphenous vein during acute hypoxia-reoxygenation: Role of glycogen, AMP-activated protein kinase, and insulin-independent glucose uptake.

Authors:  Rajkumar Pyla; Prahalathan Pichavaram; Arwa Fairaq; Mary Anne Park; Mark Kozak; Vinayak Kamath; Vijay S Patel; Lakshman Segar
Journal:  Biochem Pharmacol       Date:  2015-07-23       Impact factor: 5.858

10.  Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.

Authors:  Michael Beck
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.